[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers].
A Phase II Study of single oral administration of SF-SP containing sustained-release granules of tegafur was conducted in 37 cases of advanced cancers by 9 institutions in the Hokkaido area. Two capsules each containing 200 or 250 mg of SF-SP were orally administered twice daily for a total of either 800 or 1000 mg per day. The results were as follows: Of the 24 evaluable cases PR was observed in 4 cases. (16.7%) The observed efficacy rate by cancer type was 23.5% for gastric cancer and toxicity was observed in 10 (27.8%) of 35 subject cases. These results thus indicate SF-SP to be therapeutically effective for treatment of gastric cancers, with mild toxicity.